Skip to main content

Kurt R Brunden, PhD

Research Professor and Director of Drug Discovery, Center for Neurodegenerative Disease Research at University of Pennsylvania

Location: Philadelphia, PA United States

Dr. Brunden oversees drug discovery programs in the areas of Alzheimer’s disease, frontotemporal lobar degeneration and Parkinson’s disease. Prior to joining the Penn faculty, he served as a vice president leading drug discovery programs in two public biotechnology companies. Earlier in his career, he was an NIH-funded faculty member within the Biochemistry Department at the University of Mississippi Medical Center. Dr. Brunden received a BS from Western Michigan University, with biology and health chemistry majors, a PhD in biochemistry from Purdue University, and completed a post-doctoral fellowship at the Mayo Clinic. He recently served as chair of the NSD-C translational research study section for NIH-NINDS, and serves as an ad hoc reviewer for NIH-NINDS and NIH-NCATS. He is also an advisor for the Alzheimer’s Drug Discovery Foundation and an ad hoc reviewer for multiple scientific journals. Dr. Brunden has over 75 publications and a number of patents.

Associated Grants

  • Evaluation of the Microtubule-Stabilizing Agent, Epothilone D, in Mouse Models of Parkinson's Disease


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.